At what enterprise value was FINMED GROUP acquired in 2025?

You can find the full valuation details of FINMED GROUP on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of FINMED GROUP when it was acquired by ASKER HEALTHCARE GROUP?

The exact EV/EBITDA multiple for FINMED GROUP is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was FINMED GROUP acquired by ASKER HEALTHCARE GROUP?

FINMED GROUP was acquired by ASKER HEALTHCARE GROUP in 2025.

What was the revenue of FINMED GROUP at the time of the deal?

The revenue of FINMED GROUP at the time of the deal is estimated to be in the range of 25M - 50M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the FINMED GROUP acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the FINMED GROUP deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.asker.com/investors-and-media/press-releases-and-news/2025/acquisition-of-finmed-group-first-acquisition-in-france/

← DATABASE

Home Database Healthcare & PharmaFINMED GROUP

11/2025

FINMED GROUP acquired by ASKER HEALTHCARE GROUP

FRANCE Healthcare Services / Hospital Logistics REV 25M - 50M EUR

Context

Asker Healthcare Group has signed a definitive agreement to acquire 80% of the shares in Finmed Group, marking its strategic entry into the French healthcare market. This transaction serves as a platform acquisition, providing the Swedish-based group with a robust foundation to expand its presence in one of Europe's largest medical device markets. The deal was structured to ensure management continuity, with Finmed's leadership, including Elie Fiani and Jean-Marc Soghomonian, remaining at the helm to drive the next phase of development. The rationale for the operation is highly strategic for both parties: for Asker, Finmed provides critical local expertise and access to a wide network of French hospitals and pharmacies, while for Finmed, the integration into a larger pan-European group provides the financial firepower and technical resources needed to accelerate innovation and pursue its own external growth. The partnership aims to professionalize Finmed's organizational structure and governance while leveraging Asker's centers of excellence to enhance the service offering for French clients.

FINMED GROUP, which reported an EBITDA margin of LOGIN in 2024, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded as a family-led organization, Finmed Group is a prominent French distributor and solution provider for the medical technology sector. The company specializes in the commercialization of medical devices, equipment, and related consumables, operating through a multi-channel model that includes direct sales, specialized resellers, and e-commerce platforms. Finmed serves a broad spectrum of healthcare stakeholders, including pharmacies, public and private hospitals, and various healthcare institutions across France. Its value proposition is centered on the democratization of medical innovation, ensuring that cutting-edge technologies are accessible to both healthcare professionals and patients. The group’s strategy emphasizes operational excellence and customer satisfaction, acting as a trusted intermediary between global medical manufacturers and the domestic healthcare market. By providing integrated services alongside its product portfolio, Finmed supports the modernization of French medical infrastructure, maintaining a strong focus on professional development and corporate social responsibility (CSR) to ensure sustainable impact in the European healthcare landscape.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
01/2026	TPG	OPTUM UK	UNITED KINGDOM	Healthcare Services	TPG is in advanced negotiations to acquire Optum UK from UnitedHealth Group. This transaction follows UnitedHealth’s relatively short ownership of the asset, which it acquired in 2023 after an intensive regulatory review by the UK Competition and Markets Authority
01/2026	PERMIRA	CARNE GROUP	IRELAND	Healthcare Services	Permira has reached an agreement to acquire a significant minority stake in Carne Group. The transaction facilitates the complete exit of Vitruvian Partners (who invested in 2021) and other minority shareholders
11/2025	EURAZEO	EXCELYA	FRANCE	Healthcare Services	The management team of Excelya selected Eurazeo to invest as a minority partner with a ticket composed of a mix of equity (capped at 20%) and quasi-equity instruments, alongside a senior debt package. The transaction facilitated a partial liquidity event for the co-founding partner, who remains a minority shareholder, while providing the company with substantial firepower to pursue further international acquisitions
10/2025	EVOLEM	APPERTON	FRANCE	Healthcare Services	A French healthcare player specializing in the sterilization of reusable medical equipment has restructured its capital through a secondary MBO. Operating as a mission-critical infrastructure partner within the healthcare sector, the company commands high barriers to entry rooted in stringent clinical regulations and non-discretionary hospital decontamination mandates
05/2025	FIVE ARROWS	HUBLO	FRANCE	Healthcare Services	Hublo enters a new phase of its development by welcoming Five Arrows as its new lead shareholder. This transaction marks a transition from Venture Capital to Private Equity (Primary LBO). The entry of Five Arrows aims to provide Hublo with the strategic and financial resources to consolidate its leadership in France and accelerate its expansion in Europe, particularly in Germany and Northern Europe
04/2025	KERSIA	NEOGEN (ANIMAL BIOSECURITY DIVISION)	UNITED STATES	Healthcare Services	Kersia is acquiring the animal biosecurity cleaners and disinfectants business from Neogen® through an exclusive agreement. This strategic transaction marks a major entry for the French group into the North American swine and poultry markets, complementing its existing domestic presence in the ruminant sector
04/2025	TRANSCARENT	ACCOLADE	UNITED STATES	Healthcare Services	Transcarent completed its acquisition of Accolade on April 8, 2025, following a definitive agreement announced on January 8, 2025. The transaction is structured as a full‑takeover, with Accolade ceasing to be a Nasdaq‑listed company and becoming a privately held subsidiary within the combined group
07/2024	ARDIAN	MASCO GROUP	ITALY	Healthcare Services	Ardian acquired a majority stake in Masco Group from RSBG Infrastructure (the investment arm of the RAG-Stiftung). The transaction marks a new phase of international expansion for Masco, which has grown significantly through acquisitions such as Stilmas, Olsa, and BCD Engineering
05/2024	21 INVEST / OAKLEY CAPITAL INVESTMENTS	PRODUCT LIFE	FRANCE	Healthcare Services	21 Invest France acquired a majority stake in ProductLife Group from its founder who sought to institutionalize the company and secure resources for its next growth phase. The transaction was structured to allow the management team to reinvest significantly alongside 21 Invest
10/2023	MOTION EQUITY PARTNERS	BANOOK	FRANCE	Healthcare Services	Motion Equity Partners acquired a majority stake in Banook Group from Turenne Sante. The transaction was structured as a growth-oriented LBO, with the management team and Turenne Sante reinvesting substantially

REFERENCES

Revenue range: 25M - 50M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of FINMED GROUP by ASKER HEALTHCARE GROUP are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Acquirer: asker healthcare group